GRAMD2B

Across TCGA pan-cancer cohorts, GRAMD2B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GRAMD2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GRAMD2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GRAMD2B is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

LUAD, PDAC, and HNSC are the cancer types where GRAMD2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRAMD2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.596	<.001	9	view →
PDAC	All	All	+0.380	<.001	8	view →
HNSC	Male	II,III,IV	−0.473	.002	6	view →
LSCC	All	All	+0.173	.020	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

GRAMD2B–LUAD

Open the LUAD breakdown →